ArticleEuropean radiology2026
Robust deep learning for incomplete MRI sequences in glioma grading and IDH mutation status prediction: a large-scale multicenter study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesIncomplete MRI sequences pose a significant challenge to the reliability of multiparametric MRI (mp-MRI) radiomics models. This study aimed to develop a robust and noninvasive approach for accurate glioma grading and isocitrate dehydrogenase (IDH) mutation status prediction using incomplete MRI data. MATERIALS AND
methodsConventional MRI scans of 2170 glioma patients were retrospectively collected from five clinical institutions and a public dataset. Radiomic features extracted from each sequence, including incomplete ones, were processed using a robust incomplete sequence estimation network (RISEN). This model imputes missing features and learns latent fusion representations for glioma grading and IDH mutation status prediction. Model performance was evaluated by determining the optimal combination of mp-MRI sequences and simulating various clinical scenarios with different rates of missing data, using the area under the curve (AUC).
resultsThe optimal sequence combination of T1WI, CE-T1WI, and T2-FLAIR achieved the highest performance for glioma grading (AUC: 0.8160, 0.9136, 0.8031) and IDH prediction (AUC: 0.8657, 0.8731, 0.7682) in internal and external validation datasets with complete data. In simulated incomplete-sequence scenarios, RISEN exhibited only moderate declines for glioma grading (mean AUC: 0.7942, 0.8955, 0.7759) and IDH prediction (mean AUC: 0.8454, 0.8478, 0.7414). Comparable robustness was observed in real-world missing-sequence data (AUC: 0.8910 and 0.8854, respectively).
conclusionRISEN demonstrates robust and clinically applicable performance for glioma grading and IDH mutation prediction across multiple cohorts, even under commonly encountered incomplete mp-MRI conditions. KEY POINTS: Question Incomplete MRI sequences present a major challenge for radiomics-based glioma grading and IDH mutation status prediction in real-world clinical settings. Findings The proposed RISEN model imputes missing features using latent representations, improving model robustness and maintaining high predictive performance across various missing data scenarios. Clinical relevance RISEN offers a reliable solution for real-world glioma diagnosis when MRI sequences are incomplete, ensuring consistent clinical decision-making and personalized therapy planning across diverse imaging conditions.
Indexed as
Identifiers
42142114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.